- FIH phase I dose escalation and dose expansion study of anti-EGFR ADC MRG003 in patients with advanced solid tumorsQiu, M.; Guo, Y.; Guo, W.; Nian, W.; Liao, W.; Xu, Z.; Zhang, W.; Zhang, Y.; Wei, X.; Xue, L.; Tang, W.; Wu, Y.; Ren, G.; Wang, L.; Xi, J.; Wang, Y.; Li, M.; Hausheer, F.; Hu, C.; Xu, R.Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2021-09-16 To 2021-09-21.
- EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumorsAggarwal, Charu; Azzoli, Christopher G.; Spira, Alexander I.; Solomon, Benjamin J.; Le, Xiuning; Rolfo, Christian; Planchard, David; Felip, Enriqueta; Wu, Yi-Long; Ahn, Myung-Ju; Seiwert, Tanguy Y.; Goto, Koichi; Azaro, Analia; Lissa, Delphine; Hamid, Oday; McGrath, Lara; Maudsley, Rhiannon; Arnaldez, Fernanda I.; Grenga, Italia; Massarelli, ErminiaAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
- First-in-human/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumorsWu, J.; Zhang, J.; Li, H.; Wang, X.; Zhang, Q. Y.; Shi, Y.; Yan, M.; Pan, Y.; Shen, A.; Chen, Q.; Rao, Q.; Wei, H.; Li, C.; Yang, L.; Huang, Q.; Cao, Z.; Wu, Q.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
会议论文
Phase I study of SHR-A2009, a HER3-targeted ADC, in advanced solid tumors
4阅读
